We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Invitrogen and Emiliem Sign Major Kinase Screening Agreement

Invitrogen and Emiliem Sign Major Kinase Screening Agreement

Invitrogen and Emiliem Sign Major Kinase Screening Agreement

Invitrogen and Emiliem Sign Major Kinase Screening Agreement

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Invitrogen and Emiliem Sign Major Kinase Screening Agreement "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Invitrogen Corporation has announced a partnership with Emiliem, Inc. to screen the company’s multi-kinase inhibitors using Invitrogen’s SelectScreen™ platform.

Invitrogen will perform biochemical kinase screening, cellular pathway profiling and P450 screening of Emiliem’s compounds targeting cancer. 

“We are fortunate to have a partner with the highest technical and scientific standards in the industry and unmatched cellular screening assays,” said Dale E. Johnson, Pharm.D., Ph.D., President and CEO of Emiliem. “We view Invitrogen as a key component of our research arm in our quest to bring innovative therapeutics to cancer patients.”

Invitrogen’s SelectScreen™ profiling and screening service integrates industry-leading enzyme collections and cell-lines with state-of-the-art bioassay technologies to accelerate drug discovery programs.

The first phase of the agreement will use the SelectScreen™ kinase profiling system to confirm specificity and potency of compounds in the Emiliem pipeline created through its K-STAR technology – a proprietary drug design platform for creating compounds that inhibit multiple kinases and other cellular targets known to be important in cancer progression.

The second phase will use Invitrogen’s SelectScreen™ cell-based pathway profiling service to interrogate the effects of Emiliem’s compounds on biological pathways and the company’s cytochrome P450 profiling service to determine the inhibitory profiles of lead molecules against drug metabolizing liver enzymes.

“Our services will provide critical information to Emiliem, including confirmation that Emiliem’s compounds act on the kinases they are targeted to, determination of the compounds’ effects on specific biological pathways and prediction of potential toxicity,” noted Nick Ecos, Vice President and General Manager of Invitrogen's Discovery Sciences business.

“Our selection for this research partnership demonstrates our strong credentials in kinase biology and small molecule screening.”